Benzoxazinone compounds as KLK5/7 dual inhibitors

1. A compound represented by formula (I):

or a pharmaceutically acceptable complex thereof; wherein R is H or a member selected from the group consisting of —R 1 and —C(O)R 1a , wherein R 1 is C 1-12 alkyl, and R 1a is H or C 1-12 alkyl.

2. The compound of claim 1 , represented by formula (Ia):

or a pharmaceutically acceptable complex thereof.

3. The compound of claim 1 , represented by formula (Ib):

or a pharmaceutically acceptable complex thereof.

4. The compound of claim 1 , represented by formula (Ic):

or a pharmaceutically acceptable complex thereof.

5. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable complex thereof.

6. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable complex thereof.

7. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7 , wherein said compound has the formula:

or a pharmaceutically acceptable complex thereof.

9. The pharmaceutical composition of claim 7 , wherein said compound has the formula:

or a pharmaceutically acceptable complex thereof.

10. The pharmaceutical composition of claim 7 , prepared for topical administration.

11. A method of treating Netherton Syndrome in a subject in need thereof, comprising administering to said subject an effective amount of a compound having a formula selected from the group consisting of:

or a pharmaceutically acceptable complex thereof.

12. The method in accordance with claim 11 , wherein said compound has the formula:

or a pharmaceutically acceptable complex thereof.

13. The method in accordance with claim 11 , wherein said compound has the formula:

or a pharmaceutically acceptable complex thereof.

14. The method in accordance with claim 11 , wherein said compound is administered topically.